The blueprint for a life-saving drug can often be found in the intricate, three-dimensional architecture of a single protein, yet viewing this structure with perfect clarity has remained a persistent challenge for modern science. For pharmaceutical researchers, this microscopic world is the
The 44 new drugs that gained approval from the FDA's Center for Drug Evaluation and Research in 2025 represented far more than a simple numerical milestone; they collectively heralded a fundamental paradigm shift in the landscape of therapeutic development. This pivotal year was defined not by the
With the devastating journey of an amyotrophic lateral sclerosis (ALS) diagnosis often taking more than a year, the search for a faster, more accurate method is a top priority in neuroscience. Biopharma expert Ivan Kairatov joins us to discuss a groundbreaking new approach that uses the power of
For decades, the blueprint of disease has been read one letter at a time, searching for single genetic misspellings, yet this approach has consistently fallen short of explaining the full narrative of complex illnesses like cancer. The emergence of AI-driven gene network analysis represents a
Today we're joined by Ivan Kairatov, a biopharma expert at the forefront of medical diagnostics. For decades, the cornerstone of blood analysis has been the microscope, a tool reliant on human interpretation. But what if we could teach a machine to see the invisible signs of disease in a single
Today we're joined by Ivan Kairatov, a biopharma expert at the forefront of integrating artificial intelligence into oncology. His team’s latest work, leveraging data from the landmark TAILORx trial, has produced an AI model that significantly refines our ability to predict long-term recurrence
